Abbott Laboratories (NYSE:ABT) Given New $113.00 Price Target at Daiwa Capital Markets

Abbott Laboratories (NYSE:ABT) had its price target dropped by equities research analysts at Daiwa Capital Markets from $136.00 to $113.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The firm presently has an “outperform” rating on the healthcare product maker’s stock. Daiwa Capital Markets’ target price suggests a potential upside of 3.37% from the stock’s previous close.

Several other research firms have also recently commented on ABT. Argus reduced their target price on Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday. Citigroup cut their price target on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Mizuho upped their price objective on Abbott Laboratories from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, October 14th. Finally, Wells Fargo & Company lifted their target price on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $138.40.

Abbott Laboratories Trading Up 3.0%

NYSE ABT opened at $109.31 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The business’s fifty day moving average is $122.77 and its 200-day moving average is $127.49. Abbott Laboratories has a one year low of $105.27 and a one year high of $141.23. The stock has a market capitalization of $190.08 billion, a price-to-earnings ratio of 29.39, a PEG ratio of 1.69 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the prior year, the firm earned $1.34 EPS. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Institutional Trading of Abbott Laboratories

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank bought a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $3,026,180,000. Laurel Wealth Advisors LLC boosted its stake in shares of Abbott Laboratories by 13,347.0% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock worth $823,804,000 after acquiring an additional 6,011,891 shares in the last quarter. Invesco Ltd. increased its stake in shares of Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after purchasing an additional 4,713,135 shares in the last quarter. Vanguard Group Inc. boosted its position in Abbott Laboratories by 1.8% during the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after purchasing an additional 2,977,715 shares in the last quarter. Finally, Ninety One UK Ltd purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $336,815,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.